PRESBIA PLC (NASDAQ:LENS) Files An 8-K Other Events

On March 13, 2017, Presbia PLC (the “Company”) issued a press release announcing the closing of its previously disclosed rights offering (the “Rights Offering”), to which it raised approximately $10.8 million in gross proceeds through the sale of 3,611,764 of its ordinary shares. The subscription price was $3.00 per whole share. The Rights Offering was made to a registration statement on Form S-1 previously filed with the Securities and Exchange Commission (the “SEC”) and declared effective by the SEC on January 26, 2017.  

A copy of the press release is attached as Exhibit 99.1 hereto.

Item 901. Financial Statements and Exhibits.

(d) Exhibits

Exhibit

99.1 Press Release dated March 13, 2017.

About PRESBIA PLC (NASDAQ:LENS)
Presbia PLC is an ophthalmic device company. The Company develops and markets an optical lens implant for treating presbyopia, the age-related loss of the ability to focus on near objects. The Company’s segment is the restoration of clear vision caused by presbyopia. The Company provides the refractive lens for patient surgeries and accessories for procedures performed exclusively outside the United States. The Company’s lens, referred to as the microlens, is a miniature lens designed to be surgically implanted in a patient’s eye to improve that patient’s ability to see objects at close distances. The microlens is a disc shaped lens that has a refractive zone in the periphery designed to improve near vision problems associated with presbyopia and a central zone that is designed to improve distance vision. The Company’s solution is a standalone solution for plano presbyopes, or those individuals suffering from presbyopia but do not have any other visual disorders. PRESBIA PLC (NASDAQ:LENS) Recent Trading Information
PRESBIA PLC (NASDAQ:LENS) closed its last trading session 00.00 at 3.14 with 19,763 shares trading hands.